High-dose cyclophosphamide for severe systemic lupus erythematosus

Douglas Gladstone, A. A. Prestrud, A. Pradhan, M. J. Styler, D. L. Topolsky, P. A. Crilley, S. Hoch, A. Huppert, I. Brodsky

Research output: Contribution to journalArticle

Abstract

Cytotoxic therapy is a cornerstone for patients with severe systemic lupus erythematosus (SLE). High-dose cyclophosphamide, 200 mg/kg, can induce a complete remission without the need for stem cell rescue in patients with autoimmune illnesses. Here we report on our first four patients treated for severe SLE with this treatment approach. Patients received cyclophosphamide, 200 mg/kg, divided over 4 days. Starting day 10, patients received filgrastim, 5 μg/kg/day, until their absolute neutrophil count (ANC) rose to 10.0 × 109/1 for two consecutive days. Disease activity as evaluated by scores from the Systemic Lupus Activity Measure-2, the SLE Disease Activity Index and the Responder Index for Lupus Erythematosus were completed before and after high-dose therapy. Before high-dose cyclophosphamide, SLE disease duration ranged from 8 to 21 (mean 12.5) years. Their average disease activity measured by SLAM-2 and SLEDAI was 15.5 (range 11-19) and 23.25 (range 20-26), respectively. At a median of 22 (range 12-39) months of follow-up, mean disease activity measured by SLAM-2 and SLEDAI decreased to 6.25 and 7.75, respectively. All patients experienced febrile neutropenia. No long-term morbidities or mortalities were observed. High dose cyclophosphamide is a therapy capable of decreasing disease severity in poor prognosis SLE patients. Future study is warranted for both refractory patients as well as primary therapy for patients with moderate to severe disease presentations.

Original languageEnglish (US)
Pages (from-to)405-410
Number of pages6
JournalLupus
Volume11
Issue number7
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Systemic Lupus Erythematosus
Cyclophosphamide
Therapeutics
Febrile Neutropenia
Neutrophils
Stem Cells
Morbidity
Mortality

Keywords

  • Cyclophosphamide
  • High-dose therapy
  • SLAM
  • SLE
  • SLEDAI

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Gladstone, D., Prestrud, A. A., Pradhan, A., Styler, M. J., Topolsky, D. L., Crilley, P. A., ... Brodsky, I. (2002). High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus, 11(7), 405-410. https://doi.org/10.1191/0961203302lu229oa

High-dose cyclophosphamide for severe systemic lupus erythematosus. / Gladstone, Douglas; Prestrud, A. A.; Pradhan, A.; Styler, M. J.; Topolsky, D. L.; Crilley, P. A.; Hoch, S.; Huppert, A.; Brodsky, I.

In: Lupus, Vol. 11, No. 7, 2002, p. 405-410.

Research output: Contribution to journalArticle

Gladstone, D, Prestrud, AA, Pradhan, A, Styler, MJ, Topolsky, DL, Crilley, PA, Hoch, S, Huppert, A & Brodsky, I 2002, 'High-dose cyclophosphamide for severe systemic lupus erythematosus', Lupus, vol. 11, no. 7, pp. 405-410. https://doi.org/10.1191/0961203302lu229oa
Gladstone D, Prestrud AA, Pradhan A, Styler MJ, Topolsky DL, Crilley PA et al. High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus. 2002;11(7):405-410. https://doi.org/10.1191/0961203302lu229oa
Gladstone, Douglas ; Prestrud, A. A. ; Pradhan, A. ; Styler, M. J. ; Topolsky, D. L. ; Crilley, P. A. ; Hoch, S. ; Huppert, A. ; Brodsky, I. / High-dose cyclophosphamide for severe systemic lupus erythematosus. In: Lupus. 2002 ; Vol. 11, No. 7. pp. 405-410.
@article{8625e40576ed431680766e6fae96b388,
title = "High-dose cyclophosphamide for severe systemic lupus erythematosus",
abstract = "Cytotoxic therapy is a cornerstone for patients with severe systemic lupus erythematosus (SLE). High-dose cyclophosphamide, 200 mg/kg, can induce a complete remission without the need for stem cell rescue in patients with autoimmune illnesses. Here we report on our first four patients treated for severe SLE with this treatment approach. Patients received cyclophosphamide, 200 mg/kg, divided over 4 days. Starting day 10, patients received filgrastim, 5 μg/kg/day, until their absolute neutrophil count (ANC) rose to 10.0 × 109/1 for two consecutive days. Disease activity as evaluated by scores from the Systemic Lupus Activity Measure-2, the SLE Disease Activity Index and the Responder Index for Lupus Erythematosus were completed before and after high-dose therapy. Before high-dose cyclophosphamide, SLE disease duration ranged from 8 to 21 (mean 12.5) years. Their average disease activity measured by SLAM-2 and SLEDAI was 15.5 (range 11-19) and 23.25 (range 20-26), respectively. At a median of 22 (range 12-39) months of follow-up, mean disease activity measured by SLAM-2 and SLEDAI decreased to 6.25 and 7.75, respectively. All patients experienced febrile neutropenia. No long-term morbidities or mortalities were observed. High dose cyclophosphamide is a therapy capable of decreasing disease severity in poor prognosis SLE patients. Future study is warranted for both refractory patients as well as primary therapy for patients with moderate to severe disease presentations.",
keywords = "Cyclophosphamide, High-dose therapy, SLAM, SLE, SLEDAI",
author = "Douglas Gladstone and Prestrud, {A. A.} and A. Pradhan and Styler, {M. J.} and Topolsky, {D. L.} and Crilley, {P. A.} and S. Hoch and A. Huppert and I. Brodsky",
year = "2002",
doi = "10.1191/0961203302lu229oa",
language = "English (US)",
volume = "11",
pages = "405--410",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - High-dose cyclophosphamide for severe systemic lupus erythematosus

AU - Gladstone, Douglas

AU - Prestrud, A. A.

AU - Pradhan, A.

AU - Styler, M. J.

AU - Topolsky, D. L.

AU - Crilley, P. A.

AU - Hoch, S.

AU - Huppert, A.

AU - Brodsky, I.

PY - 2002

Y1 - 2002

N2 - Cytotoxic therapy is a cornerstone for patients with severe systemic lupus erythematosus (SLE). High-dose cyclophosphamide, 200 mg/kg, can induce a complete remission without the need for stem cell rescue in patients with autoimmune illnesses. Here we report on our first four patients treated for severe SLE with this treatment approach. Patients received cyclophosphamide, 200 mg/kg, divided over 4 days. Starting day 10, patients received filgrastim, 5 μg/kg/day, until their absolute neutrophil count (ANC) rose to 10.0 × 109/1 for two consecutive days. Disease activity as evaluated by scores from the Systemic Lupus Activity Measure-2, the SLE Disease Activity Index and the Responder Index for Lupus Erythematosus were completed before and after high-dose therapy. Before high-dose cyclophosphamide, SLE disease duration ranged from 8 to 21 (mean 12.5) years. Their average disease activity measured by SLAM-2 and SLEDAI was 15.5 (range 11-19) and 23.25 (range 20-26), respectively. At a median of 22 (range 12-39) months of follow-up, mean disease activity measured by SLAM-2 and SLEDAI decreased to 6.25 and 7.75, respectively. All patients experienced febrile neutropenia. No long-term morbidities or mortalities were observed. High dose cyclophosphamide is a therapy capable of decreasing disease severity in poor prognosis SLE patients. Future study is warranted for both refractory patients as well as primary therapy for patients with moderate to severe disease presentations.

AB - Cytotoxic therapy is a cornerstone for patients with severe systemic lupus erythematosus (SLE). High-dose cyclophosphamide, 200 mg/kg, can induce a complete remission without the need for stem cell rescue in patients with autoimmune illnesses. Here we report on our first four patients treated for severe SLE with this treatment approach. Patients received cyclophosphamide, 200 mg/kg, divided over 4 days. Starting day 10, patients received filgrastim, 5 μg/kg/day, until their absolute neutrophil count (ANC) rose to 10.0 × 109/1 for two consecutive days. Disease activity as evaluated by scores from the Systemic Lupus Activity Measure-2, the SLE Disease Activity Index and the Responder Index for Lupus Erythematosus were completed before and after high-dose therapy. Before high-dose cyclophosphamide, SLE disease duration ranged from 8 to 21 (mean 12.5) years. Their average disease activity measured by SLAM-2 and SLEDAI was 15.5 (range 11-19) and 23.25 (range 20-26), respectively. At a median of 22 (range 12-39) months of follow-up, mean disease activity measured by SLAM-2 and SLEDAI decreased to 6.25 and 7.75, respectively. All patients experienced febrile neutropenia. No long-term morbidities or mortalities were observed. High dose cyclophosphamide is a therapy capable of decreasing disease severity in poor prognosis SLE patients. Future study is warranted for both refractory patients as well as primary therapy for patients with moderate to severe disease presentations.

KW - Cyclophosphamide

KW - High-dose therapy

KW - SLAM

KW - SLE

KW - SLEDAI

UR - http://www.scopus.com/inward/record.url?scp=0036024149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036024149&partnerID=8YFLogxK

U2 - 10.1191/0961203302lu229oa

DO - 10.1191/0961203302lu229oa

M3 - Article

C2 - 12195780

AN - SCOPUS:0036024149

VL - 11

SP - 405

EP - 410

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 7

ER -